Fresenius SE Shares Outstanding 2016-2024 | FSNUY
Fresenius SE shares outstanding history from 2016 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Fresenius SE shares outstanding for the quarter ending June 30, 2024 were 2.261B, a 0.34% increase year-over-year.
- Fresenius SE 2023 shares outstanding were 2.253B, a 0.35% increase from 2022.
- Fresenius SE 2022 shares outstanding were 2.245B, a 0.56% increase from 2021.
- Fresenius SE 2021 shares outstanding were 2.233B, a 0.07% increase from 2020.
Fresenius SE Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
2,253 |
| 2022 |
2,245 |
| 2021 |
2,233 |
| 2020 |
2,231 |
| 2019 |
2,230 |
| 2018 |
2,229 |
| 2017 |
2,230 |
| 2016 |
2,200 |
| 2015 |
2,193 |
Fresenius SE Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
2,261 |
| 2024-03-31 |
2,253 |
| 2023-12-31 |
2,253 |
| 2023-09-30 |
2,253 |
| 2023-06-30 |
2,253 |
| 2023-03-31 |
2,253 |
| 2022-12-31 |
2,245 |
| 2022-09-30 |
2,253 |
| 2022-06-30 |
2,240 |
| 2022-03-31 |
2,234 |
| 2021-12-31 |
2,233 |
| 2021-09-30 |
2,232 |
| 2021-06-30 |
2,231 |
| 2021-03-31 |
2,231 |
| 2020-12-31 |
2,231 |
| 2020-09-30 |
2,218 |
| 2020-06-30 |
2,222 |
| 2020-03-31 |
2,231 |
| 2019-12-31 |
2,230 |
| 2019-09-30 |
2,248 |
| 2019-06-30 |
2,216 |
| 2019-03-31 |
2,229 |
| 2018-12-31 |
2,229 |
| 2018-09-30 |
2,235 |
| 2018-06-30 |
2,222 |
| 2018-03-31 |
2,230 |
| 2017-12-31 |
2,230 |
| 2017-09-30 |
2,231 |
| 2017-06-30 |
2,222 |
| 2017-03-31 |
2,231 |
| 2016-12-31 |
2,200 |
| 2016-09-30 |
2,200 |
| 2016-06-30 |
2,200 |
| 2016-03-31 |
2,200 |
| 2015-12-31 |
2,182 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$20.921B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
